Rash was more frequent with erlotinib plus gemcitabine than with gemcitabine alone, and we observed the association between rash and a better outcome that has been seen in other pancreatic cancer studies of EGFR inhibitors [3, 33, 34]. Here, EGFR is linked to pancreatic neoplasm.